cll 13q deletion life expectancy

Another indicator is that your blood may also contain too few red blood cells and platelets. Bookshelf Chronic Lymphocytic Leukemia: Prognosis and Outlook. 2M, WBC count, Hb, unmated IGVH, abnormal karyotype, splenomegaly, MRD positivity at 12 months have a significant impact on PFS. You also have the option to opt-out of these cookies. Administration UD of VA Veterans Health. Even so, its important to let your doctor know if you have any CLL symptoms. Chronic lymphocytic leukemia - cancer stat facts. CLL is a disease that usually impacts older adults. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. (2018). ASH 2022: Dr. Talha Munir on How IGHV Mutation Status of Chronic Lymphocytic Leukemia (CLL) Affects Response to Combination Ibrutinib Plus Venetoclax, ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53Mutation, CLL Societys COVID-19 Update for the Week of February 20, 2023, Karen Jones on Warm Autoimmune Hemolytic Anemia and wAIHA Warriors, 4) Deletions on the short arm of chromosome 17 (del(17p)). Hence, it is imperative to get information about individual patient prognosis in order to define a therapeutic strategy and to allow patients to plan their lives moving forward. In HELIOS, pts with R/R CLL/SLL (excluding del17p) received BR (6 cycles) with or without ibr 420 mg/day (starting on day 2 of cycle 1) followed by single-agent ibr or placebo continued until PD or tox. Treatments are designed to help you manage symptoms, plus slow down the progression of the disease. Thank you, {{form.email}}, for signing up. -, Leukemia. See this image and copyright information in PMC. You can find out more about our use, change your default settings, and withdraw your consent at any time with effect for the future by visiting Cookies Settings, which can also be found in the footer of the site. However, there is currently no cure for this disease. Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. ClinicalTrials.gov. -, Molecular pathogenesis of chronic lymphocytic leukemia. RESULTS: Of 134 patients 63% (n=84) were male and 37% (n=50) female, and median age was 60 (range 35-83) yrs. Life expectancy (unrelated to CLL) Existing comorbidities, performance status Deep remission Effective but less toxic Do no harm having Binet stage B or C chronic lymphocytic leukaemia. MNT is the registered trade mark of Healthline Media. The range and severity of symptoms may vary greatly, depending upon the exact size and location of the deletion on 13q. As a result, clinical trials are now being designed to test therapies in various subgroups of patients to predict disease progression, improve response and prolong patient survival. Ninety six percent (n=129) patients had non bulky disease and only 4 (3%) had bulky disease. If you have questions or concerns, talk to your doctor or to other members of your CLL team, such as a therapist or social worker. Chronic lymphocytic leukemia (CLL) is the most common leukemic disease in elderly patients. Clipboard, Search History, and several other advanced features are temporarily unavailable. The cells for each form are slightly different, but doctors can only tell them apart by testing them in a laboratory. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. The presentation and course of CLL is strikingly varied in patients, with some individuals presenting with a biologically indolent course whereas others present with an aggressive course. Susan M. O'Brien, MD: There's 1 group [of patients for whom I] always use BTK inhibitors, and those would be the patients who have a 17p deletion or a TP53 mutation. Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Fo R, Guarini A, Gattei V. Genes Chromosomes Cancer. Analytical cookies are used to understand how visitors interact with the website. Furthermore, the size of deletion of the long arm of chromosome 13 (13q) has a remarkable effect on its prognosis and therapeutic intervention. Posted By : / actual instructions in flowcharting are represented in /; Under :nose exercise before and afternose exercise before and after Purpose: To further our understanding of the biology and prognostic significance of various chromosomal 13q14 deletions in chronic lymphocytic leukemia (CLL).Experimental Design: We analyzed data from SNP 6.0 arrays to define the anatomy of various 13q14 deletions in a cohort of 255 CLL patients and have correlated two subsets of 13q14 deletions (type I exclusive of RB1 and type II . Splenomegaly was present in 55 (41%) and absent in 76 (57%). Doctors can only very rarely cure CLL. Find out more about what happens to blood cells in this disorder and its. The Rai system is comprised of five stages, from 0 to 4, that are grouped into three risk groups: To determine CLL stage, the Rai system takes these factors into account: There is currently no cure for CLL. Unable to load your collection due to an error, Unable to load your delegates due to an error, PI3K, phosphoinositide 3 kinases; BCR, B cell receptors; BTK, Bruton tyrosine kinase; BCL2, B cell lymphoma 2; Abs, antibodies; CAR-T, chimeric antigen receptor T cell; CLL, chronic lymphocytic leukemia Copyright/License LicenseeThe JSLTR, Japan. 2014 Sep;53(9):788-97. doi: 10.1002/gcc.22188. The prognosis for CLL is much higher than for many other types of cancer. The four most common chromosomal aberrations that are detected using "FISH" studies at diagnosis are: 1) Deletions on the long arm of chromosome 13 (del (13q14)) (present in 55%) 2) Deletions on the long arm of chromosome 11 (del (11q23)) (present in 18%) 3) Trisomy 12 . 2020;50(SI-2):1679-1690. doi:10.3906/sag-2005-327, Evans J, Ziebland S, Pettitt AR. Chemotherapy, combined with monoclonal antibody treatment, is a standard protocol used for fighting this disease. If the condition is at an early stage, it may not need treatment. However, 4-5% of CLL patients carry a TP53 mutation in the absence of del (17p). You have 23 pairs of chromosomes (46 total) and . Watchful waiting entails observation without starting treatment. 2004-2023 Healthline Media UK Ltd, Brighton, UK, a Red Ventures Company. cajunjeff 2 years ago. SEER. 2001 Jun;15(6):981-6. doi: 10.1038/sj.leu.2402125. In conclusion, the deletion of 13q varied in size both in CLL and in other . Bethesda, MD 20894, Web Policies evident when grouping the partial deletion of 13q and monosomy 13 together (as frequently done in . ATM is the gene located on the q arm of the 11th chromosome. Those with later-stage disease may have uncomfortable side effects from CLL and its treatments. CLL is not curable. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional. The severity of the condition and the signs and symptoms depend on the size and location of the deletion and which genes are involved. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: different genetic mechanisms but equivalent poorer clinical outcome. Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling, Typical treatment of chronic lymphocytic leukemia, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Vaccine therapy for treating patients with previously untreated chronic lymphocytic leukemia (CLL), Chronic lymphocytic leukemia treatment (PDQ)patient version, Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule, Incurable, invisible and inconclusive: watchful waiting for chronic lymphocytic leukaemia and implications for doctor-patient communication, Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century, Chronic lymphocytic leukemia in young ( 55 years) patients: a comprehensive analysis of prognostic factors and outcomes, Swollen lymph nodes in the armpits, neck, groin, and stomach, Inability to stave off repeated infections, Getting sick easily with conditions such as colds and the, Enlargement of the lymph nodes, spleen, and liver, Platelet count (whether it is low, indicating thrombocytopenia), Red blood cell count (whether it is low, indicating anemia). []del(17p) is associated with mutated TP53 and with poor response rates and short duration of response to the standard therapeutic options. An 87% 5-year survival rate means that around 87 out of every 100 people with CLL will be alive 5 years after diagnosis. In CLL, too many lymphocytes (a type of white blood cell) are produced from a single cell line (monoclonal). Fluorescence in situ hybridization (FISH) based prognostic factors. Getting emotional support and expressing feelings can help. These abnormal lymphocytes do not function as they should, impairing the bodys ability to fight infection. Research is ongoing and continues to prolong survival and improve the quality of life for people with this condition. A high number of B cells, one type of lymphocyte, may indicate chronic lymphocytic leukemia. Cerebral ultrasound at 6 days of life showed slightly asymmetric lateral . Since CLL doesnt usually cause tumors, it is not a standard therapy for this condition. Humplikova L, Kollinerova S, Papajik T, Pikalova Z, Holzerova M, Prochazka V, Divoka M, Modriansky M, Indrak K, Jarosova M. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;20(6):377-83. doi: 10.1016/j.semcancer.2010.10.012. Tam CS, Shanafelt TD, Wierda WG, et al. Federal government websites often end in .gov or .mil. ~Trisomy 12 is considered an intermediate risk chromosomal aberration and its impact on therapeutic choices is presently unknown. Survival rates can give a person more information about the outlook for their condition and help them plan treatment and care. What to know about atypical chronic myeloid leukemia, What to know about the history of chronic myeloid leukemia, an increase in WBC levels and enlargement of lymph nodes, an increase in WBC and enlargement of lymph nodes, spleen, or liver, an increase in WBC levels, low number of red blood cells, enlargement of lymph node, spleen, or liver, an increase in WBC levels, low number of red blood cells and platelets, enlargement of lymph nodes, spleen, or liver, whether CLL has come back or improved with treatment, how cancer cells have spread in the bone marrow. However, low-dose radiation may be used if you have an enlarged spleen or swollen lymph nodes in a specific area. The most frequent are heterozygous and homozygous 13q deletions (44%), but also alterations such as trisomy 12 and 17p deletions have been detected (Fazi et al. However, as leukemia affects the blood, doctors cannot stage it in this way. Furthermore, the overproduction of these cells means they may begin to build up in bone marrow, impeding the production of normal WBCs, and the proper working of red blood cells and platelets. CLL staging. CLL starts in one of the types of white blood cells found in the bone marrow. Cutting-edge treatments, including the use of monoclonal antibodies (mAbs, proteins made in a lab to fight infection) and targeted therapies (using drugs or other substances to identify and attack certain cancer cells), are helping people live longer and with fewer symptoms than in decades past. Trisomy 12 means that there are lymphocytes that contain an extra chromosome 12 (you are only supposed to have two copies). Typical treatment of chronic lymphocytic leukemia. Some experts have also proposed it to be a tool that could assist in decision to initiate therapy. -, Genomic aberrations and survival in chronic lymphocytic leukemia. Median OS was not reached. It is possible to have this condition for many years before you start to show symptoms. Novel drugs and their target molecules and pathways. (. Leukemia is a type of cancer that affects the bone marrow and blood. The 10-year survival rate for CLL is approximately 64.7%. sharing sensitive information, make sure youre on a federal DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma. A lot of patients know that 17p deletions is one of the high risk markers in CLL - but there are a lot of things to consider about CLL with 17p deletion before completely tearing your hair out. Doctors can very rarely cure CLL. Many people find living with a lifelong condition challenging. Although I haven't shown it, the median age of survivors . Federal government websites often end in .gov or .mil. As such, the imbalance contributes towards B cells' immortality and, thus, CLL arises. Having more than 5,000 lymphocytes per cubic millimeter of blood strongly indicates CLL. The site is secure. Chronic lymphocytic leukemia (chronic lymphoid leukemia, CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally incompetent lymphocytes (see the image below). SNP array analysis revealed the common deletion of a 15 Mb (13.3 to 14.3) region of 13q in 7 13q and 13q patients. Treatments include: Watch and wait: If youre in a low-risk stage and have no outward symptoms, watchful waiting may be the first recommended course of action. More importantly pooled data from three randomized phase 3 studies showed that del11q was not a prognostic factor for adverse outcomes for patients with CLL. Chronic lymphocytic leukemia stages. What is chronic lymphocytic leukemia? Chronic Lymphocytic Leukemia: What Are the Differences? Abstract. American Cancer Society. Survival rate for chronic lymphocytic leukemia. We avoid using tertiary references. Chronic Myeloid Leukemia vs. . Necessary cookies are absolutely essential for the website to function properly. Dhner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Kim H, Hur M, Moon HW, Park CM, Yun YM, Kim SY. Regarding CLL treatment, conventional therapy with alkylating agents has been used for a long time, which reported low- to non-existent complete remission rates and adverse events after prolonged use. Whereas patients who have a 17p deletion, which affects p53 or 11q deletion, which affectsATM, these patients unfortunately have a worsened prognosis than patients who have no abnormalities. These cookies ensure basic functionalities and security features of the website, anonymously. What to Eat When You Have Chronic Lymphocytic Leukemia? The sharp decline in life expectancy with time is largely due to the high percentage of older people in the group. If a person does have symptoms, they may include the following: There are two types of CLL. Fluorescence in situ hybridization (FISH) based prognostic factors. 2 Monoallelic 13q14 deletions are present in nearly 70% of patients with CLL, while biallelic and . Other common CLL changes include deletions in chromosomes 11 and 17 [del(11q) and del(17q)], and trisomy 12, which is an extra copy of chromosome 12. Douglas A. Nelson, MD, is a board-certified oncologist and hematologist who previously served for 13 years as a physician in the US Air Force. CLL International Prognostic Index (CLL-IPI). Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. 13q deletion 178(55) 11q deletion 58(18) trisomy 12 53(16) 17p deletion 23(7) 6q deletion 21(6) Dohner et al. Of 51 patients who experienced disease progression, there were 8 observed deaths. It is used to give an estimate of the percentage of people who will survive their cancer. How Chronic Lymphocytic Leukemia (CLL) Is Treated, How Waldenstrom Macroglobulinemia Is Diagnosed and Treated, Rituxan (Rituximab) for Non-Hodgkin Lymphoma, CLL, and More, Smart Patients Chronic Lymphocytic Leukemia Community, Key statistics for chronic lymphocytic leukemia. Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia. It can be overwhelming to learn you have an incurable condition. 2016;9(1):28. doi:10.1186/s13045-016-0257-2, Parikh SA, Rabe KG, Kay NE, et al. This patient has trisomy 12, which was sort of . The median survival times (the time by which point half of the patients are alive, the other half dead) for the groups with 17p deletion, 11q deletion, 12q trisomy, normal karyotype, and 13q deletion as the sole abnormality were 32, 79, 114 . a higher blood level of a protein called beta 2 microglobulin. Monoclonal antibodies: Monoclonal antibodies target and destroy a specific target, such as proteins on the surface of cancer cells. Vaccine therapy for treating patients with previously untreated chronic lymphocytic leukemia (CLL). Here, learn about its symptoms, treatments, outlook, and, Chronic lymphocytic leukemia (CLL) affects lymphocytes, which are a type of white blood cell. Median PFS was 83.1 mths (6.9 years), OS at 5 years was 89.9%, and at 10 years was 79.1%. When told I had chronic lymphocytic leukemia (CLL) four years ago, all I heard was "leukemia". However, you may visit "Cookie Settings" to provide a controlled consent. 2012;122:34323438. Unmutated IGHV portends a poor survival and shorter treatment-free interval. -, The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Those under the age of 40 are unlikely to experience this type of cancer. Learn about CLL diagnosis, staging, symptoms, and, Atypical chronic myeloid leukemia is a blood and bone marrow cancer. In CLL, the most common DNA mutation is a deletion in chromosome 13 [del(13q)]. 2020 Sep 14;21(18):6720. doi: 10.3390/ijms21186720. People with CLL may benefit from gentle exercise and following a healthy, balanced diet. In the Rai system, a person will have blood tests to check for cancer cells and determine how many white blood cells are in the blood and bone marrow. Several types of monoclonal antibodies are used to combat CLL. Once they occur, symptoms may include: The survival rate for CLL is better than for many other types of cancer. Thomas Kipps, MD, PhD. Data doesnt currently indicate that a 20-year survival rate is common or likely with CLL. The cookie is used to store the user consent for the cookies in the category "Performance". CLL may cause fatigue. The survival rate for CLL is better than for many other types of cancer. Haematologica. Heart failure: Could a low sodium diet sometimes do more harm than good? HHS Vulnerability Disclosure, Help We analyzed this group of patients treated with FCR to characterize the relationship between clinico-biological parameters and outcome. These strategies may help: Be an advocate for your own care. In the low-cell variant, progression into CLL is rare. The Rai system divides CLL into 5 stages: Decades later, physicians still use the Rai stages as a way of describing the level of risk from CLL for each patient. People with CLL may not have any symptoms for years. del(13q) is a favorable prognostic marker (median overall survival [OS], 17 years in one prospective study). Genes Chromosomes Cancer. Some studies have shown that combination chemoimmunotherapy, containing alkylating agents may overcome the negative prognostic implications of del11q. PMC The second type progresses more quickly and is typically to be more severe. Importance of genetics in chronic lymphocytic leukemia. Chronic B-cell leukemias and Agent Orange - public health. Previous studies showed that, in chronic lymphocytic leukemia (CLL) patients with isolated 13q deletion (13q-), those carrying higher percentage of . Would you like email updates of new search results? Abdul Rashid Shah, Tariq Muzzafar, Romana Asad, Christine B Peterson, Hagop M. Kantarjian, Alessandra Ferrajoli, William G Wierda, Jan A. Burger, Nitin Jain, Gautam Borthakur, Maliha Khan, Abhishek Chilkulwar, Brion Randolph, Lohith Gowda, Michael J Keating; Chronic Lymphocytic Leukemia with Deletion 13q: Prognostic Predictors and Outcome after . Puiggros A, Venturas M, Salido M, Blanco G, Fernandez-Rodriguez C, Collado R, Valiente A, Ruiz-Xivill N, Carri A, Ortuo FJ, Luo E, Calasanz MJ, Ardanaz MT, Pin M, Talavera E, Gonzlez MT, Ortega M, Marugn I, Ferrer A, Gimeno E, Bellosillo B, Delgado J, Hernndez J, Hernndez-Rivas JM, Espinet B; Grupo Cooperativo Espaol de Citogentica Hematolgica (GCECGH); Grupo Espaol de Leucemia Linftica Crnica (GELLC). It is rare for treatment to cure CLL, but it can successfully manage the condition. How Viagra became a new 'tool' for young men, Ankylosing Spondylitis Pain: Fact or Fiction, Learn more about breakthroughs in CLL treatment, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf, https://www.nhs.uk/conditions/chronic-lymphocytic-leukaemia/, https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq, https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/detection-diagnosis-staging/staging.html, https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/key-statistics.html, https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/after-treatment/follow-up.html, https://www.cancerresearchuk.org/about-cancer/what-is-cancer/understanding-cancer-statistics-incidence-survival-mortality, https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html, Cardiovascular health: Insomnia linked to greater risk of heart attack. A stem cell transplant uses immature cells called stem cells to replace cancerous bone marrow. Hematol Oncol Clin North Am. 2017 Aug;92:864-869. doi: 10.1016/j.biopha.2017.05.144. Transcript: William Wierda, MD, PhD: We've done quite a bit of work with prognostic factors in CLL and looked at predictive markers for time-to-first-treatment, predictive markers for how . We performed fluorescence in situ hybridization (FISH) studies with 13q locus-specific LSI-D13S25 and LSI-RB1 probes. Older adults are more likely to have CLL than others, with 70 years being the average age of diagnosis. Chromosome 13, Partial Monosomy 13q is usually apparent at birth and may be characterized by low birth weight, malformations of the head and facial (craniofacial) area, abnormalities of the eyes, defects of the hands and/or . Medical News Today has strict sourcing guidelines and draws only from peer-reviewed studies, academic research institutions, and medical journals and associations. Chronic myeloid leukemia (CML) is a type of blood cancer that medical professionals first described in the 1840s. Blood 2017; 130 (Supplement 1): 5337. doi: https://doi.org/10.1182/blood.V130.Suppl_1.5337.5337. The .gov means its official. This cookie is set by GDPR Cookie Consent plugin. [] del(17p) is associated with the most . Chronic lymphocytic leukemia (CLL) is diagnosed in more than 15 000 cases annually, contributing to 5000 deaths yearly. Balanced translocations in parents are a rare cause of de novo RB1 deletions in offspring. government site. 11q23 deletion is linked to the ataxia-telangiectasia mutated gene and is detected in 5-20% CLL patients. Targeted therapy: Targeted drugs may also be used as a first-line CLL treatment. 2M >4 (HR 1.85, p=0.02), high WBC count (HR 1.55, p<0.01), Hb <10 gm/dL (p=0.01), unmated IGVH (HR 2.78, p=0.001), abnormal karyotype (HR 2.01, p=0.04), splenomegaly (HR 2.45, p=0.001), MRD positivity at 12 months (HR 2.87, p=0.01) had a significant negative impact on PFS. This significant 13q14 deletion contributes to CLL's pathogenesis and paves the way for CLL treatment, hence affecting the prognosis of the affected patients. Around 85% of people with chronic lymphocytic leukemia (CLL) live for 5 or more years following diagnosis. Dealing with an incurable illness is never easy. Stevens-Kroef MJ, van den Berg E, Olde Weghuis D.Identification of prognostic relevant chromosomal abnormalities in chronic lymphocytic leukemia using microarray-based genomic profiling. When possible, enroll a friend or exercise buddy to tag along. MeSH Keywords: Can poor sleep impact your weight loss goals? Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. Vaccine therapy. cll 13q deletion life expectancyplymouth township mi police scanner. Zhou W, Goldin L, Wang M, McMaster ML, Jones K, Burdett L, Chanock SJ, Yeager M, Dean M, Caporaso NE. Disclaimer. Experts suggest that a lymphocyte doubling time of less than 6 months may be a measure to define initiation of therapy. Net survival. When you visit the site, Dotdash Meredith and its partners may store or retrieve information on your browser, mostly in the form of cookies. al. Lymphocytes are a type of white blood cell. Epub 2013 Sep 5. (2018). Chronic lymphocytic leukemia treatment (PDQ)patient version. Ann Clin Lab Sci. Chronic lymphocytic leukemia (CLL) is the most prevalent type of adult leukemia and is defined by a typical immunophenotype of mature B-cell markers (CD19, CD20[dim], CD23, sIg [dim]) with coexpression of the T-cell marker CD5. CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. Watchful waiting is not a passive treatment. Men are slightly more likely to get this condition than women. Deletion of chromosome 17p [del(17p)] distinguishes a subgroup of patients with chronic lymphocytic leukaemia (CLL) and an exceptionally poor prognosis (Hillmen et al, 2007; Hallek et al, 2010; Zenz et al, 2010, 2012; Badoux et al, 2011).Although uncommon at the time of diagnosis (generally <5%) (Juliusson et al, 1990), the percentage of patients with CLL whose disease harbours del(17p .

My Time At Portia Checklist, Lake Michigan Water Temperatures By Month, Articles C